News

Modifying the dose of Esbriet (pirfenidone) can effectively reduce the number of treatment-related adverse events without affecting the drug’s potential to manage idiopathic pulmonary fibrosis (IPF), a new retrospective analysis of data from Phase 3 clinical trials shows. The findings of this recent post-hoc analysis were published in…

The idiopathic pulmonary fibrosis (IPF) treatment candidate BBT-877 eased lung fibrosis (scarring) in a mouse model, according to South Korea-based Bridge Biotherapeutics. The company believes that BBT-877 may become the “best-in-class” medication for IPF. Data from a preclinical study on BBT-877 was presented at the 2nd Annual IPF…

A plant-based medicine called quercetin reversed pulmonary fibrosis in a mouse model likely by reducing the burden of growth-arrested and fibrosis-promoting cells, called senescent cells, in the animals’ lungs, researchers report. Findings were published in the study, “Quercetin enhances ligand-induced apoptosis in senescent IPF fibroblasts and reduces lung…

Surgery for lung cancer should be carefully considered in patients who also have idiopathic pulmonary fibrosis (IPF), because it is associated with poor outcomes, a study shows. The study, “Survival after repeated surgery for lung cancer with idiopathic pulmonary fibrosis: a retrospective study,” was published in the journal…

Tiny extracellular vesicles that carry information from one cell to another may contribute to the development of idiopathic pulmonary fibrosis (IPF) by carrying molecules involved in the disease, a study has found. The study, “Increased Extracellular Vesicles Mediate WNT-5A Signaling in Idiopathic Pulmonary Fibrosis,” was published in the…

Lung cancer and acute exacerbations are significant predictors of mortality in patients with combined pulmonary fibrosis and emphysema, according to researchers. Their study, “Presence of lung cancer and high gender, age, and physiology score as predictors of acute exacerbation in combined pulmonary fibrosis and emphysema: A…